C2 Blockchain Expands DOG Treasury to 600 Million, Advancing Institutional Adoption of Bitcoin-Native Digital Assets
Trinity Capital (Nasdaq: TRIN) announced a $45 million growth capital commitment to Rapid Micro Biosystems (Nasdaq: RPID) to support scaling of the Growth Direct platform and global commercial expansion.
The funding is designated to accelerate manufacturing scale, fund product cost reductions, improve service productivity, and drive gross margin expansion, with the stated goal of strengthening Rapid Micro's financial position and supporting long-term revenue growth and shareholder value.
Trinity Capital (Nasdaq: TRIN) ha annunciato un impegno di capitale di crescita di $45 million a Rapid Micro Biosystems (Nasdaq: RPID) per sostenere la scalabilità della piattaforma Growth Direct e l'espansione commerciale globale.
Il finanziamento è destinato ad accelerare la scala di produzione, finanziare la riduzione dei costi di prodotto, migliorare la produttività del servizio e guidare l'espansione del margine lordo, con l'obiettivo dichiarato di rafforzare la posizione finanziaria di Rapid Micro e supportare la crescita dei ricavi a lungo periodo e il valore per gli azionisti.
Trinity Capital (Nasdaq: TRIN) anunció un compromiso de capital de crecimiento de $45 millones para Rapid Micro Biosystems (Nasdaq: RPID) para apoyar la escalabilidad de la plataforma Growth Direct y la expansión comercial global.
La financiación se destina a acelerar la escalabilidad de la fabricación, financiar reducciones de coste de los productos, mejorar la productividad del servicio y impulsar la expansión del margen bruto, con el objetivo declarado de fortalecer la posición financiera de Rapid Micro y apoyar el crecimiento de ingresos a largo plazo y el valor para los accionistas.
Trinity Capital (나스닥: TRIN)은 Rapid Micro Biosystems(Nasdaq: RPID)에 대해 성장 자본 약정 4,500만 달러를 발표하여 Growth Direct 플랫폼의 확장 및 글로벌 상업적 확장을 지원합니다.
이번 자금은 제조 규모 확장 가속화, 제품 원가 절감 비용, 서비스 생산성 향상 및 총마진 확장을 추진하는 데 배정되며, Rapid Micro의 재무 상태를 강화하고 장기 매출 성장 및 주주 가치를 지원한다는 목적이 명시되어 있습니다.
Trinity Capital (Nasdaq: TRIN) a annoncé un engagement en capital de croissance de 45 millions de dollars en faveur de Rapid Micro Biosystems (Nasdaq: RPID) pour soutenir l'extension de la plateforme Growth Direct et l'expansion commerciale mondiale.
Le financement est destiné à accélérer l'augmentation des capacités de fabrication, à financer des réductions de coût des produits, à améliorer la productivité du service et à stimuler l'augmentation de la marge brute, avec l'objectif déclaré de renforcer la position financière de Rapid Micro et de soutenir la croissance des revenus à long terme et la valeur pour les actionnaires.
Trinity Capital (Nasdaq: TRIN) kündigte eine Wachstumsfinanzierung in Höhe von 45 Millionen USD zugunsten von Rapid Micro Biosystems (Nasdaq: RPID) an, um die Skalierung der Growth Direct-Plattform und die globale kommerzielle Expansion zu unterstützen.
Die Finanzierung soll die Produktionskapazität beschleunigen, Produktkostensenkungen finanzieren, die Serviceproduktivität verbessern und die Bruttomarge steigern, mit dem ausdrücklichen Ziel, die finanzielle Situation von Rapid Micro zu stärken und das langfristige Umsatzwachstum sowie den Wert für die Aktionäre zu unterstützen.
Trinity Capital (ناسداك: TRIN) أعلنت عن التزام رأس مال نمو قدره $45 مليون لشركة Rapid Micro Biosystems (ناسداك: RPID) لدعم توسع منصة Growth Direct وتوسعها التجاري العالمي.
يخصص التمويل لتسريع تصنيع السلاسل، وتمويل خفض تكلفة المنتج، وتحسين إنتاجية الخدمة، ودفع توسع الهامش الإجمالي، مع الهدف المعلن لتقوية الوضع المالي لـ Rapid Micro ودعم نمو الإيرادات على المدى الطويل وقيمة المساهمين.
- $45 million committed in growth capital to Rapid Micro
- Capital to support global commercial expansion of Growth Direct platform
- Funding targeted to drive gross margin expansion via cost and efficiency initiatives
- Company cites support for long-term revenue growth and shareholder value
- None.
Rapid Micro specializes in automating microbial quality control in mission-critical applications such as environmental monitoring, water testing, sterility testing, and bioburden testing. The Company's Growth Direct® platform provides faster results, greater accuracy, increased operational efficiency, and stronger data integrity, enabling customers to make quicker decisions that help ensure a safe and consistent supply of important healthcare products.
"In an industry where quality cannot be compromised, Rapid Micro Biosystems is delivering the automation and dependability manufacturers need," said Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital. "They are transforming a critical process within biopharma manufacturing, and we are proud to partner with a team driving meaningful impact across the industry."
This new capital will help scale Rapid Micro's operations, to include supporting the continued global commercial expansion of the Growth Direct platform, and ongoing investments to drive gross margin expansion through product cost reduction, increased manufacturing efficiencies, and service productivity.
"We are pleased to partner with Trinity Capital, who shares our vision of automating manual microbial quality control testing methods used in biopharma manufacturing," said Robert Spignesi, President and CEO of Rapid Micro Biosystems. "This facility significantly strengthens our financial position and supports our continued focus on long-term revenue growth, margin expansion, and increasing shareholder value."
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ("MQC") testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-45-million-in-growth-capital-to-rapid-micro-biosystems-modernizing-healthcare-industry-practices-302562036.html
SOURCE Trinity Capital Inc.
FAQ
What did Trinity Capital announce about Rapid Micro on November 18, 2025?
How will the $45 million from Trinity Capital be used by Rapid Micro (RPID)?
Does the announcement state how the $45 million affects Rapid Micro's financial position?
What product does Rapid Micro plan to scale with Trinity Capital's investment?
Which Nasdaq tickers are mentioned in the announcement?
